Gene therapy for neurofibromatosis type 1
Generated by a Claude Opus 4.7 agent (max thinking effort, 1M-context). Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
Neurofibromatosis type 1 (NF1)
Modality
Gene Therapy
Mechanism
AAV gene replacement
Target
NF1
rNPV Envelope
Low
-$43.5M
costs +25% · peak −25%
Base
$27.0M
cumulative PoS 10.8%
High
$97.4M
costs −25% · peak +25%
NF1 AAV is costed like a rare pediatric gene therapy with higher early CMC spend but smaller pivotal studies. Koselugo anchors NF1 clinical/regulatory precedent; Zolgensma and UX111 anchor AAV pricing, trial size, and BLA timing.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.80
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.692 — composite-score rank #3 of 10 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#2) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
Koselugo (AstraZeneca/Merck) — selumetinib
Approved NF1 therapy establishing regulatory feasibility and disease-market precedent.
Criteria 2 and 3: same indication and pediatric orphan NF1 pathway, though symptom-modifying rather than gene replacement.
Zolgensma (Novartis) — onasemnogene abeparvovec
One-time AAV economics benchmark for pediatric monogenic disease.
Criteria 3 and 4: same rare pediatric AAV gene-therapy modality and premium-pricing model.
UX111 (Ultragenyx) — rebisufligene etisparvovec
Late-stage AAV CNS orphan program anchoring small pivotal trial and BLA timing.
Criteria 3 and 4: same rare pediatric CNS AAV pathway with expedited regulatory features.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $28.0M | 24 mo | 56.0% | [1] [2] [5] |
| Phase I | $85.0M | 18 mo | 72.0% | [1] [2] [5] |
| Phase II | $190.0M | 30 mo | 48.0% | [0] [2] [5] |
| Phase III | $260.0M | 30 mo | 62.0% | [0] [2] [5] |
| NDA/BLA Review | $18.0M | 12 mo | 90.0% | [0] [2] [5] |
Multiplier handling: Eligible multipliers (genetic_validation_2.6x, biomarker_1.7x, orphan_1.4x, gene_therapy_1.41x, fast_track_or_rmat, pediatric_voucher) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$900.0M peak · WACC 12.0%
Peak revenue. Revenue is modeled above Koselugo because root-cause AAV could command one-time gene-therapy pricing, but below Zolgensma because NF1 penetrance and lesion heterogeneity complicate addressability. The $900M peak assumes pediatric plexiform neurofibroma first use with later expansion optionality.
WACC. Genetically defined orphan AAV development is risky but squarely within venture-backed rare-disease playbooks.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV ($27.0M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$306.3M
P25
-$147.9M
P50 (median)
-$37.3M
P75
-$15.7M
P95
$1.16B
Prob ≥ 0
10.2%
Comparable launch curves
Revenue trajectories of named comparators
Koselugo (AstraZeneca/Merck) — selumetinib
Launched 2020 · peak $475.0M (estimated)
Evidence register
6 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
NF1 approved-therapy comparator comparators[0] | NCI Cancer Currents: Selumetinib approved for NF1 plexiform neurofibromas regulatory | 2020-05-08 | high |
Koselugo commercial/regulatory precedent peak_revenue_usd | Merck press release: Koselugo approved by FDA for pediatric NF1 plexiform neurofibromas news | 2020-04-10 | high |
Zolgensma AAV economics benchmark comparators[1] | Novartis Annual Report 2024 company_filing | 2025-01-31 | high |
UX111 late-stage AAV orphan comparator comparators[2] | ClinicalTrials.gov NCT02716246: AAV gene transfer for MPS IIIA trial_disclosure | 2016-03-25 | high |
UX111 follow-up and pivotal timing stage_profile.phase_3.duration_months | ClinicalTrials.gov NCT04088734: long-term follow-up after ABO-102 gene transfer trial_disclosure | 2019-09-12 | high |
Rare gene-therapy PoS adjustment stage_profile.phase_2.pos | BIO/QLS/Informa Clinical Development Success Rates 2011-2020 peer_review | 2021-02-17 | medium |
Thesis
Why this asset earns its top-10 rank
The NF1 AAV asset is a root-cause gene-replacement concept engineered around AAV's ~4.7 kb packaging limit: full-length NF1 (~8.5 kb CDS) cannot fit in a single AAV, so the asset uses a mini-NF1 construct — a truncated GAP-related domain (GRD) fused to the KRAS4B C-terminal targeting domain — paired with an in-vivo-evolved capsid (AAV-NF K55) developed via sequential capsid shuffling and peptide library screening. The 2025 Nature Communications paper from the JHU group demonstrates tumor suppression in xenograft mouse models of NF1-related cancers. The asset's top-10 position comes from strong genetic validation, pediatric orphan fit, and a credible disease-modification thesis that addresses the gene-size constraint head-on rather than papering over it.
Koselugo proves that NF1 plexiform neurofibroma is an approvable commercial indication, while Zolgensma and UX111 anchor rare pediatric AAV economics and development cost. The engine result is -$43.5M to $97.4M, with a base rNPV of $27.0M and cumulative PoS of 10.8%; that supports the VC-fundable archetype if the initial program focuses on a high-need, genetically confirmed NF1 subgroup with tractable delivery and measurable lesion endpoints.
The verdict is a credible rare-disease gene-therapy deep dive that earns its ranking on engineered-vector merit, not on naive gene-replacement framing. The main remaining questions are whether GRD-only neurofibromin restores enough RAS-GAP activity in vivo to drive durable lesion regression, and whether the AAV-NF K55 capsid achieves the tissue distribution NF1's multisystem pathology demands.
Key risks
Asset-specific, not generic biotech risks
- NF1 disease is multisystem; even an evolved capsid (AAV-NF K55) may not reach all relevant lesion compartments — plexiform neurofibroma is the lead but cutaneous neurofibromas, optic pathway gliomas, and MPNST may need separate delivery strategies.
- GRD-only neurofibromin retains catalytic RAS-GAP activity in xenografts but lacks domains that may be required for full physiologic regulation; whether catalytic-only restoration delivers durable clinical benefit at scale is unproven.
- Koselugo sets a symptom-modifying standard that may raise expectations for measurable tumor shrinkage rather than growth inhibition.
- Pediatric gene-therapy safety monitoring could slow development even with orphan incentives, and engineered-capsid redosing carries vector-immunity risk specific to the AAV-NF K55 sequence.